# Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy

> **NCT05410938** · — · COMPLETED · sponsor: **Far Eastern Memorial Hospital** · enrollment: 59 (actual)

## Conditions studied

- Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer

## Interventions

- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT05410938
- **Lead sponsor:** Far Eastern Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-06
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2023-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05410938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05410938, "Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05410938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*